Holm-Jorgensen Rasmus 4
4 · Acrivon Therapeutics, Inc. · Filed Nov 27, 2024
Insider Transaction Report
Form 4
Holm-Jorgensen Rasmus
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-03-01+90,090→ 90,090 totalExercise: $5.70Exp: 2034-02-28→ Common Stock (90,090 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.